Literature DB >> 2166749

Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus.

W M Dankner1, D Scholl, S C Stanat, M Martin, R L Sonke, S A Spector.   

Abstract

A rapid DNA-DNA hybridization technique that can be accomplished in 4 to 5 days was compared with plaque reduction assay to determine its reliability in performing antiviral assays for human cytomegalovirus (HCMV). The assay involves lysing infected cells, direct wicking of denatured DNA onto membranes and hybridization using a 125I-labeled HCMV DNA probe. Using ten ganciclovir sensitive clinical HCMV strains for comparison, the DNA hybridization technique correlated well with the plaque assay. Clinical HCMV strains previously identified as resistant to ganciclovir were also readily identified. The DNA-DNA hybridization assay is less tedious and more rapid than plaque reduction assays, and thus, provides an excellent alternative for evaluation of the antiviral activity of drugs against HCMV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2166749     DOI: 10.1016/0166-0934(90)90122-v

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  17 in total

1.  Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents.

Authors:  M Marschall; M Freitag; S Weiler; G Sorg; T Stamminger
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures.

Authors:  J M Pepin; F Simon; A Dussault; G Collin; M C Dazza; F Brun-Vezinet
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

Review 3.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.

Authors:  S C Stanat; J E Reardon; A Erice; M C Jordan; W L Drew; K K Biron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.

Authors:  N S Lurain; A Weinberg; C S Crumpacker; S Chou
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples.

Authors:  G Gerna; A Sarasini; E Percivalle; M Zavattoni; F Baldanti; M G Revello
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus.

Authors:  J G Jacobson; T E Renau; M R Nassiri; D G Sweier; J M Breitenbach; L B Townsend; J C Drach
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 8.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

9.  Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.

Authors:  D A Jabs; C Enger; M Forman; J P Dunn
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

10.  Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.

Authors:  M A Slavin; R R Bindra; C A Gleaves; M B Pettinger; R A Bowden
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.